

LISTING AND AMENDMENT OF THE CLAIMS:

1. (Previously presented) A soft gelatin capsule containing a pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form characterised in that the capsule comprises gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source.
2. (Original) A soft gelatin capsule as claimed in Claim 1 wherein formulation comprises 5, 8, 11, 14, 17-eicosapentaenoic acid (or "EPA").
3. (Original) A soft gelatin capsule as claimed in Claim 2 wherein EPA is present in an amount of at least about 50 wt % of the formulation.
4. (Currently amended) A soft gelatin capsule as claimed in Claim 2 ~~or Claim 3~~ wherein EPA is present in an amount of between from about 50 wt % to about 60 wt % of the formulation.
5. (Currently amended) A soft gelatin capsule as claimed in Claim 2 ~~or Claim 3~~ wherein EPA is present in an amount of at least about 90 wt % of the formulation.
6. (Currently amended) A soft gelatin capsule as claimed in ~~any one of Claims 1, 2 or 3~~ Claim 1 wherein the formulation comprises 4, 7, 10, 13, 16, 19-docosahexaenoic acid (or "DHA").
7. (Previously presented) A soft gelatin capsule as claimed in Claim 6 wherein DHA is present in an amount of between from about 20 wt % to about 30 wt % of the formulation.
8. (Currently amended) A soft gelatin capsule as claimed in ~~any one of Claims 1, 2~~

Serial Number: 10/587,201
Attorney Docket: SACH3001/ESS

~~or 3~~ Claim 1 comprising between from about 100mg to about 2000mg of said formulation.

9. (Previously presented) A soft gelatin capsule as claimed in Claim 8 comprising about 500mg of said formulation.

10. (Previously presented) A soft gelatin capsule as claimed in Claim 8 comprising about 1000mg of said formulation.

11. (Canceled)

12. (Canceled)

13. (Currently amended) A soft gelatin capsule as claimed in ~~any one of Claims 1, 2 or 3~~ Claim 1 wherein the gelatin comprises porcine gelatin.

14. (Currently amended) A soft gelatin capsule as claimed in ~~any one of Claims 1, 2 or 3~~ Claim 1 wherein the gelatin comprises bovine gelatin.

15. (Currently amended) A soft gelatin capsule as claimed in ~~any one of Claims 1, 2 or 3~~ Claim 1 wherein the gelatin comprises fish gelatin.

16. (Previously presented) A soft gelatin capsule as claimed in Claim 1 wherein the wall of the capsule consists of a single layer.

17. (Previously presented) A soft gelatin capsule as claimed in Claim 1 wherein the capsule delays release of the formulation until after passage through the stomach.

18. (Previously presented) A soft gelatin capsule as claimed in Claim 1 wherein the

Serial Number: 10/587,201
Attorney Docket: SACH3001/ESS

capsule delays release of the formulation until after passage beyond the pancreatic duct in the duodenum.

19. (Currently amended) A soft gelatin capsule as claimed in Claim 17 ~~or Claim 18~~ wherein the capsule is coated with at least one enteric material.

20. (Previously presented) A soft gelatin capsule as claimed in Claim 19 wherein at least one enteric material is integrated within the gelatin of the capsule.

21. (Previously presented) A soft gelatin capsule as claimed in Claim 19 wherein the or at least one enteric material is a neutral polyacrylate polymer.

22. (Previously presented) A soft gelatin capsule as claimed in Claim 20 wherein the or at least one enteric material is poly(ethylacrylate-methylmethacrylate).

23. (Canceled)

24. (Canceled)

25. (Previously presented) A process for the manufacture of a soft gelatin capsule containing a pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form, said process comprising encapsulating said pharmaceutical formulation in gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source.

26. (Canceled)

27. (Canceled)

28. (Canceled)

29. (Canceled)

30. (Previously presented) A method of treatment or prophylaxis of a condition selected from chronic inflammatory conditions, hyperlipidaemia, hypertriglyceridaemia, asthma, bipolar disorder and neoplastic disease comprising administering a therapeutically effective amount of a pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form in the form of a plurality of soft gelatin capsules containing a pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form characterized in that the capsule comprises gelatine extracted by an extraction process comprising acid pre-treatment of a collagen source.

31. (Currently amended) A method as claimed in Claim 30 ~~wherein the soft gelatin capsules~~ wherein the omega-3 polyunsaturated fatty acid in free acid form comprises EPA.

32. (Canceled)

33. (Canceled)

34. (Canceled)